Material event report (treasury share disposal) (subsidiary)

What happened

Material event report / Matter subject to KRX reporting obligation Report on a material management matter of subsidiary Hanmi Pharm Co., Ltd. To: Financial Services Commission / Korea Exchange July 28, 2026

Company name: Hanmi Pharm Co., Ltd. CEO: Hwang Sang-yeon Head office: 214 Muha-ro, Paltan-myeon, Hwaseong-si, Gyeonggi-do (Tel) 031-350-5600 (Website) http://www.hanmi.co.kr Preparer: (Title) Deputy Managing Director (Name) Seo Kyung-ho (Tel) 02-410-9240

Treasury Share Disposal Decision

1. Shares to be disposed of: Common shares 10,402; Other shares: - 2. Price of the shares to be disposed of (KRW): Common shares 390,500; Other shares: - 3. Expected disposal amount (KRW): Common shares 4,061,981,000; Other shares: - 4. Expected disposal period: Start date July 29, 2026, End date August 28, 2026 5. Purpose of disposal: - Grant of treasury shares as a productivity incentive (PI) to employees (RSA); - Grant of treasury shares as a major-performance-contribution incentive to employees (RSU) 6. Disposal method: Pro-rata disposal to all shareholders: -; After-hours block trade: -; Off-market disposal: -; Other: 10,402 shares 7. Disposal counterparties: 644 Hanmi Pharm employees (RSA); 18 Hanmi Pharm employees (RSU) 8. Entrusted investment broker: Shinhan Investment Corp. 9. Treasury-share holdings before the disposal: Acquired within the scope of distributable profit, Common shares: -, Ratio (%): -; Other shares: -, Ratio (%): -; Other acquisitions, Common shares: 121,880, Ratio (%): 0.95; Other shares: -, Ratio (%): - 10. Holding/disposal plan: General shareholders' meeting approval date: March 31, 2026 11. Disposal decision date: July 28, 2026 - Independent (outside) director* attendance: Present (persons): 3; Absent (persons): - - Auditor (audit committee member who is not an independent/outside director*) attendance: - 12. Daily sell-order quantity limit: Common shares: -; Other shares: - * "Independent director" applies to listed companies; "outside director" applies to unlisted companies. 13. Other matters for reference in investment decisions 1) The "price of the shares to be disposed of" in Item 2 above is based on the KRX regular-market closing price on the business day before the board resolution date. 2) The "expected disposal amount" in Item 3 above is calculated by multiplying the "number of shares to be disposed of" in Item 1 by the "price of the shares to be disposed of" in Item 2. However, the expected number of shares and amount to be disposed of may change depending on performance-evaluation results, the closing price on the day before the actual disposal date, etc. 3) The "disposal method" in Item 6 above is a transfer from the company's treasury-share account to the securities accounts of the respective grant recipients. 4) The "daily sell-order quantity limit" in Item 12 above does not apply, as this is not an on-market sale through the securities market.

[Treasury share holdings before the treasury share disposal decision] (Unit: shares) Acquisition method: Acquired within the scope of distributable profit, Direct acquisition, On-market direct acquisition: Common shares, Beginning balance: -, Acquired (+): -, Disposed (-): -, Retired (-): -, Ending balance: -; Other shares: all - Off-market direct acquisition: Common shares/Other shares: all - Tender offer: Common shares/Other shares: all - Subtotal (a): Common shares/Other shares: all - Acquired under a trust agreement, Trustee-held volume: Common shares/Other shares: all - In-kind held volume: Common shares/Other shares: all - Subtotal (b): Common shares/Other shares: all - Other acquisitions (c): Common shares, Beginning balance: 130,777, Disposed (-): 8,897, Ending balance: 121,880 (Note 1); Other shares: all - Total (a+b+c): Common shares, Beginning balance: 130,777, Disposed (-): 8,897, Ending balance: 121,880 (Note 1); Other shares: all - (Note 1) The reference date for the beginning balance is January 1, 2026; the ending balance is as of the date this disclosure document was filed.

[Additional disclosure matters] 1. Relationship of each disposal counterparty with the company or the largest shareholder: Hanmi Pharm employees 2. Reason for selecting the disposal counterparties: - Grant of treasury shares as a productivity incentive (PI) under the stock-based employee compensation program (RSA); - Grant of treasury shares to employees who satisfy the grant conditions under the major-performance incentive share standards (RSU) 3. Number of shares disposed of per counterparty: Category: Productivity incentive (PI) grant (RSA); Counterparty: 644 Hanmi Pharm employees; Type and quantity of shares disposed of: 7,562 common shares. Category: Major-performance incentive grant (RSU); Counterparty: 18 Hanmi Pharm employees; Type and quantity of shares disposed of: 2,840 common shares. 4. Basis for price determination: Stated based on the KRX regular-market closing price (KRW 390,500) on the day before the board resolution date (July 27, 2026); the grant size may change depending on the performance-evaluation results of the target employees as of the actual disposal date and the closing price on the day before the actual disposal date, and accordingly the expected number of shares and amount to be disposed of may change. 5. Expected dilutive effect on share value: The treasury shares expected to be disposed of represent 0.08% of total shares outstanding (12,810,991 shares) as of the filing date, so the dilutive effect on share value is expected to be limited. 6. Other matters for reference in investment decisions: - The RSA shares will be held in custody for 1 year from the payment date. - Other detailed matters are delegated to the CEO.